Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 11

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 11
---
 Shares will only be made pursuant to the offer to purchase, the letter
of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND STOCKHOLDERS ARE URGED TO READ BOTH THE TENDER
OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO
TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS SHOULD CONSIDER BEFORE
MAKING ANY DECISION REGARDING TENDERING THEIR TARGET SHARES, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and stockholders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which will be named in the tender offer statement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Target under the “Investor Relations” section of the Target’s website athttps://www.mersana.com/.

| Item 9.01 | Financial Statements and Exhibits. |

| (d) | Exhibits. |

| Exhibit 
 Number  
 2.1*    
 10.1    |     | Description                                                                                                                                                                                                            
 Agreement and Plan of Merger, dated November 12, 2025, by and among Parent, Merger Sub and Target (incorporated herein by reference to Exhibit 2.1 of Target’s Current Report on Form 8-K filed on November 13, 2025). 
 Form of Tender and Support Agreement (incorporated herein by reference to Exhibit 2.2 of Target’s Current Report on Form 8-K filed on November 13, 2025).                                                              |
|:--------|:----|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.2    |     | Form of Contingent Value Rights Agreement (incorporated herein by reference to Exhibit 2.3 of Target’s Current Report on Form 8-K filed on November 13, 2025).                                                         |
| 99.1    |     | Press Release, dated November 13, 2025.                                                                                                                                                                                |
| 99.2    |     | Investor Presentation                                                                                                                                                                                                  |
| 99.3    |     | Corporate Presentation                                                                                                                                                                                                 |
| 104